Reduced or absent CK18 immunostaining was associated with high UICC stage (p = 0.0010), high Thoenes grade (p = 0.0086), advanced tumor stage (p < 0.0001), and poor prognosis in clear cell renal cell cancers (p = 0.0088) and with high grade and unfavorable molecular features such as ER/PR negativity (p < 0.0001 each)—but not with patient outcome—in invasive breast carcinomas of no special type. The gene discussed is ESR1; the disease is invasive breast carcinoma.